Abstract
A novel coronavirus pneumonia broke out in early 2020 in China. In order to find a certain cure, China has turned its attention to Remdesivir, which is produced by Gilead. At the initial stage, China placed high expectations on this drug, and urgently approved phase III clinical trial applications. As the epidemic in China slowed, the development of Remdesivir clinical trials also encountered the problem of insufficient number of participants, and some trials were forced to terminate early. The recent clinical trial results show that the efficacy of Remdesivir is uncertain, which has made the Chinese government's attitude towards approving the marketing authority of Remdesivir become cautious. Based on this information, we expect that it will be difficult for Remdesivir to successfully list in China in the future, and there are also some competitors try to enter the Chinese market as imported drugs. But in other ways, China can cooperate with Gilead and other manufacturing companies to solve global public health problems.
Get full access to this article
View all access options for this article.